The Role of Pembrolizumab in the Treatment of PD-L1 Expressing Gastric and Gastroesophageal Junction Adenocarcinoma

Therapeutic Advances in Gastroenterology - United Kingdom
doi 10.1177/1756284819869767
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-Junction Adenocarcinoma After Pembrolizumab

Cureus
2019English

Adenocarcinoma of the Esophago-Gastric Junction

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
1999English

P3.cr-20 the Effect of Pembrolizumab in EGFR Mutated Lung Adenocarcinoma Patients With PD-L1 Overexpression: Two Cases Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Prognostic Role of Body Composition Parameters in Gastric/Gastroesophageal Junction Cancer Patients From the EXPAND Trial

Journal of Cachexia, Sarcopenia and Muscle
OrthopedicsSports MedicinePhysiology
2019English

Bronchialkarzinom – Pembrolizumab Vorteilhaft Bei PD-L1-positiven Patienten

Pneumologie
MedicinePulmonaryRespiratory Medicine
2016English

Surgery and Clinicopathological Features of Gastric Adenocarcinoma Involving the Esophago-Gastric Junction

Kurume Medical Journal
Medicine
2005English

The Promising Role of Pembrolizumab in the Management of Patients With Pd-L1-Positive Non-Small Cell Lung Cancer: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Role of PD-L1 in the Prediction of Treatment Responses to Neoadjuvant Chemotherapy in Breast Carcinoma

Pathology
Forensic MedicinePathology
2020English

The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response

Klinicka Onkologie
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy